GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively.
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
GSK’s Vaccine Restructuring May Strengthen Cost Efficiency
The closure could ultimately strengthen GSK plc (NYSE:GSK)’s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK’s vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
If GSK’s mRNA flu candidate successfully progresses through Phase III and ultimately reaches commercialization, the company could replace declining traditional flu demand with a more differentiated product. The Phase II results are encouraging because the candidate produced stronger immune responses than currently approved standard- and high-dose vaccines across the tested populations. From a valuation perspective, disciplined capacity reduction could also reduce the risk that declining legacy vaccine volumes translate into persistent margin pressure.
GSK’s Next-Gen Vaccine Strategy Still Faces Execution Risk
The closure nevertheless highlights a structural weakness in GSK plc (NYSE:GSK)’s influenza franchise: demand for traditional flu vaccines is declining enough to make one of two dedicated manufacturing sites economically unnecessary. That creates a near-term risk that vaccine volumes and manufacturing utilization remain under pressure before newer products can compensate. The 641 affected positions also create the possibility of restructuring, severance, and other closure-related costs, while opposition from the German union and works council could make the process more complicated or expensive than a straightforward capacity reduction.
More importantly, the replacement strategy is not yet proven commercially. GSK’s mRNA flu vaccine has only reached Phase III, meaning the stronger immune responses observed in Phase II still need to translate into efficacy, regulatory approval, and meaningful market adoption. The broader industry backdrop adds another layer of risk: Reuters has reported falling vaccine sales and weaker returns across several vaccine categories, suggesting that even a technologically superior flu product could face pricing, demand, or reimbursement pressure. If traditional flu demand continues to deteriorate faster than GSK can commercialize next-generation vaccines, the Dresden closure could be evidence of a wider decline in the company’s influenza opportunity rather than simply an efficiency improvement.
Conclusion
The Dresden closure is more strategically positive than negative for GSK plc (NYSE:GSK), provided the company successfully executes the transition from traditional egg-based flu vaccines to newer technologies. Eliminating excess capacity should support cost discipline and potentially improve margins, while GSK’s broader vaccine portfolio is still growing, with £2.3 billion of quarterly vaccine sales and particularly strong momentum in meningitis and Arexvy.
However, the bear case is meaningful because the company is cutting capacity in response to real underlying demand weakness, while its key replacement opportunity, the mRNA flu vaccine, remains in Phase III. Overall, the closure should be viewed as a portfolio and cost-efficiency move rather than a signal that GSK is abandoning vaccines, but its long-term financial payoff depends heavily on whether newer vaccine technologies can offset the decline in conventional flu products.
READ NEXT: Kroger Under Pressure as Shoppers Become More Price-Sensitive and Colgate-Palmolive Seeks Value Through Portfolio Reshaping
This article is originally published at Insider Monkey.
